Across TCGA pan-cancer cohorts, HEPACAM2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated HEPACAM2 data layer compared with 22 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher HEPACAM2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HEPACAM2 expression acts as an unfavorable survival marker.

LSCC are the cancer types where HEPACAM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.310	1.000	.013	13	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: HEPACAM2 tumor-vs-normal RNA expression · all HEPACAM2 data types